tiprankstipranks
Trending News
More News >
Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
India Market

Aurobindo Pharma Ltd (AUROPHARMA) Stock Forecast & Price Target

Compare
0 Followers
See the Price Targets and Ratings of:

AUROPHARMA Analyst Ratings

Moderate Buy
4Ratings
Moderate Buy
3 Buy
0 Hold
1 Sell
Based on 4 analysts giving stock ratings to
Aurobindo
Pharma Ltd
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AUROPHARMA Stock 12 Month Forecast

Average Price Target

₹1,430.00
▲(21.25%Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Aurobindo Pharma Ltd in the last 3 months. The average price target is ₹1,430.00 with a high forecast of ₹1,700.00 and a low forecast of ₹1,140.00. The average price target represents a 21.25% change from the last price of ₹1,179.35.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1056":"₹1,056","1701":"₹1,701","1217.25":"₹1,217.3","1378.5":"₹1,378.5","1539.75":"₹1,539.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.70K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1430,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.43K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.14K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1056,1217.25,1378.5,1539.75,1701],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1229.4,1265.6000000000001,1301.8000000000002,1338,1374.2,1410.4,1446.6000000000001,1482.8000000000002,1519,1555.2,1591.4,1627.6,1663.8000000000002,{"y":1700,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1229.4,1244.8307692307694,1260.2615384615385,1275.6923076923078,1291.123076923077,1306.5538461538463,1321.9846153846154,1337.4153846153847,1352.8461538461538,1368.2769230769231,1383.7076923076922,1399.1384615384616,1414.5692307692307,{"y":1430,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1229.4,1222.523076923077,1215.646153846154,1208.769230769231,1201.8923076923077,1195.0153846153846,1188.1384615384616,1181.2615384615385,1174.3846153846155,1167.5076923076924,1160.6307692307691,1153.753846153846,1146.876923076923,{"y":1140,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1152.45,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1187,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1212.15,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1432.25,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1553.2,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1438.55,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1396,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1255.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1351.4,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1351.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1171.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1057.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1229.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target₹1,700Average Price Target₹1,430Lowest Price Target₹1,140
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Macquarie
₹1,700
Buy
44.15%
Upside
Reiterated
03/28/25
Macquarie Reiterates Outperform Rating on Aurobindo Pharma (ARBP:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR1,700.00 price target on Aurobindo Pharma (ARBP:IN).
Citi
₹1,285₹1,140
Sell
-3.34%
Downside
Reiterated
03/26/25
Aurobindo Pharma (ARBP:IN) PT Lowered to INR1,140 at CitiCiti analyst Vivek Agrawal lowered the price target on Aurobindo Pharma (ARBP:IN) to INR1,140.00 (from INR1,285.00) while maintaining a Sell rating.
HSBC
₹1,580
Buy
33.97%
Upside
Reiterated
03/21/25
HSBC Reiterates Buy Rating on Aurobindo Pharma (ARBP:IN)HSBC analyst Damayanti Kerai reiterated a Buy rating and INR1,580.00 price target on Aurobindo Pharma (ARBP:IN).
Goldman Sachs Analyst forecast on IN:AUROPHARMA
Shyam SrinivasanGoldman Sachs
Goldman Sachs
₹1,475₹1,300
Buy
10.23%
Upside
Reiterated
03/04/25
Aurobindo Pharma (ARBP:IN) PT Lowered to INR1,300 at Goldman SachsGoldman Sachs analyst Shyam Srinivasan lowered the price target on Aurobindo Pharma (ARBP:IN) to INR1,300.00 (from INR1,475.00) while maintaining a Buy rating.
ICICI Securities Analyst forecast on IN:AUROPHARMA
Abdulkader PuranwalaICICI Securities
ICICI Securities
₹1,470₹1,445
Buy
22.53%
Upside
Reiterated
02/10/25
Aurobindo Pharma Ltd. (ARBP:IN) PT Lowered to INR1,445 at ICICI SecuritiesICICI Securities analyst Abdulkader Puranwala lowered the price target on Aurobindo Pharma Ltd. (ARBP:IN) to INR1,445.00 (from INR1,470.00) while maintaining a Buy (1) rating.
CLSA
₹1,540₹1,400
Buy
18.71%
Upside
Upgraded
01/23/25
CLSA Upgrades Aurobindo Pharma (ARBP:IN) to Outperform (2)CLSA analyst Kunal Lakhan upgraded Aurobindo Pharma (ARBP:IN) from Hold (3) to Outperform (2) with a price target of INR1,400.00 (from INR1,540.00).
Kotak Mahindra Analyst forecast on IN:AUROPHARMA
Unknown AnalystKotak Mahindra
Not Ranked
Kotak Mahindra
₹1,225
Sell
3.87%
Upside
Reiterated
12/29/24
Kotak reiterates Sell (4) Rating on Aurobindo Pharma Ltd. (ARBP:IN)Kotak analyst Kumar Gaurav reiterated a Sell (4) rating and INR1,225.00 price target on Aurobindo Pharma Ltd. (ARBP:IN).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Macquarie
₹1,700
Buy
44.15%
Upside
Reiterated
03/28/25
Macquarie Reiterates Outperform Rating on Aurobindo Pharma (ARBP:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR1,700.00 price target on Aurobindo Pharma (ARBP:IN).
Citi
₹1,285₹1,140
Sell
-3.34%
Downside
Reiterated
03/26/25
Aurobindo Pharma (ARBP:IN) PT Lowered to INR1,140 at CitiCiti analyst Vivek Agrawal lowered the price target on Aurobindo Pharma (ARBP:IN) to INR1,140.00 (from INR1,285.00) while maintaining a Sell rating.
HSBC
₹1,580
Buy
33.97%
Upside
Reiterated
03/21/25
HSBC Reiterates Buy Rating on Aurobindo Pharma (ARBP:IN)HSBC analyst Damayanti Kerai reiterated a Buy rating and INR1,580.00 price target on Aurobindo Pharma (ARBP:IN).
Goldman Sachs Analyst forecast on IN:AUROPHARMA
Shyam SrinivasanGoldman Sachs
Goldman Sachs
₹1,475₹1,300
Buy
10.23%
Upside
Reiterated
03/04/25
Aurobindo Pharma (ARBP:IN) PT Lowered to INR1,300 at Goldman SachsGoldman Sachs analyst Shyam Srinivasan lowered the price target on Aurobindo Pharma (ARBP:IN) to INR1,300.00 (from INR1,475.00) while maintaining a Buy rating.
ICICI Securities Analyst forecast on IN:AUROPHARMA
Abdulkader PuranwalaICICI Securities
ICICI Securities
₹1,470₹1,445
Buy
22.53%
Upside
Reiterated
02/10/25
Aurobindo Pharma Ltd. (ARBP:IN) PT Lowered to INR1,445 at ICICI SecuritiesICICI Securities analyst Abdulkader Puranwala lowered the price target on Aurobindo Pharma Ltd. (ARBP:IN) to INR1,445.00 (from INR1,470.00) while maintaining a Buy (1) rating.
CLSA
₹1,540₹1,400
Buy
18.71%
Upside
Upgraded
01/23/25
CLSA Upgrades Aurobindo Pharma (ARBP:IN) to Outperform (2)CLSA analyst Kunal Lakhan upgraded Aurobindo Pharma (ARBP:IN) from Hold (3) to Outperform (2) with a price target of INR1,400.00 (from INR1,540.00).
Kotak Mahindra Analyst forecast on IN:AUROPHARMA
Unknown AnalystKotak Mahindra
Not Ranked
Kotak Mahindra
₹1,225
Sell
3.87%
Upside
Reiterated
12/29/24
Kotak reiterates Sell (4) Rating on Aurobindo Pharma Ltd. (ARBP:IN)Kotak analyst Kumar Gaurav reiterated a Sell (4) rating and INR1,225.00 price target on Aurobindo Pharma Ltd. (ARBP:IN).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aurobindo Pharma Ltd

1 Month
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
+1.55%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.55% per trade.
3 Months
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
+1.10%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +1.10% per trade.
1 Year
Success Rate
1/1 ratings generated profit
100%
Average Return
+2.50%
reiterated a sell rating 13 days ago
Copying Anubhav Agarwal CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +2.50% per trade.
2 Years
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
+3.55%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +3.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AUROPHARMA Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
0
0
0
0
Buy
2
3
6
11
Hold
0
0
0
1
Sell
0
0
1
4
Strong Sell
0
0
0
0
total
2
3
7
16
In the current month, AUROPHARMA has received 11 Buy Ratings, 1 Hold Ratings, and 4 Sell Ratings. AUROPHARMA average Analyst price target in the past 3 months is 1,430.00.
Each month's total comprises the sum of three months' worth of ratings.

AUROPHARMA Financial Forecast

AUROPHARMA Earnings Forecast

Next quarter’s earnings estimate for AUROPHARMA is ₹17.41 with a range of ₹17.35 to ₹17.46. The previous quarter’s EPS was ₹15.56. AUROPHARMA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AUROPHARMA has Preformed in-line its overall industry.
Next quarter’s earnings estimate for AUROPHARMA is ₹17.41 with a range of ₹17.35 to ₹17.46. The previous quarter’s EPS was ₹15.56. AUROPHARMA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AUROPHARMA has Preformed in-line its overall industry.

AUROPHARMA Sales Forecast

Next quarter’s sales forecast for AUROPHARMA is ₹85.50B with a range of ₹85.50B to ₹85.50B. The previous quarter’s sales results were ₹83.82B. AUROPHARMA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year AUROPHARMA has Outperformed its overall industry.
Next quarter’s sales forecast for AUROPHARMA is ₹85.50B with a range of ₹85.50B to ₹85.50B. The previous quarter’s sales results were ₹83.82B. AUROPHARMA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year AUROPHARMA has Outperformed its overall industry.

AUROPHARMA Stock Forecast FAQ

What is IN:AUROPHARMA’s average 12-month price target, according to analysts?
Based on analyst ratings, Aurobindo Pharma Ltd’s 12-month average price target is 1,430.00.
    What is IN:AUROPHARMA’s upside potential, based on the analysts’ average price target?
    Aurobindo Pharma Ltd has 21.25% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Aurobindo Pharma Ltd a Buy, Sell or Hold?
          Aurobindo Pharma Ltd has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Aurobindo Pharma Ltd’s share price target?
            The average share price target for Aurobindo Pharma Ltd is 1,430.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ₹1,700.00 ,and the lowest forecast is ₹1,140.00. The average share price target represents 21.25% Increase from the current price of ₹1,179.35.
              What do analysts say about Aurobindo Pharma Ltd?
              Aurobindo Pharma Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Aurobindo Pharma Ltd?
                To buy shares of IN:AUROPHARMA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis